At the annual Singapore Week of Innovation and Technology (SWITCH) 2023, Lion TCR, a clinical-stage mRNA-based T cell immunotherapy company, is thrilled to announce a significant milestone of clinching the T-Up Excellence Awards. This award, in recognition of remarkable contributions to the growth and innovation within Lion TCR and the broader Singapore biotech sector, have been also presented to Dr. Wai Lu-En, Lion TCR's Senior Director of Research and Development, and Dr. Sarene Koh, Director
Lion TCR Pte Ltd, clinical-stage biotech company specialized in the development and commercialization of its proprietary engineered T Cell Receptor (TCR) products against infectious disease and its associated cancers, has been recognized as the ‘Most Promising Cell & Gene Therapy Startup in Asia’ category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022, organized by IMAPAC.